New and updated estimates of glaucoma populations around the world;
Analysis of two new classes of glaucoma therapeutics launched in the US in 2018: nitric oxide-donating compounds and rho kinase (ROCK) inhibitors
Expanded discussions of genetics, gene therapies, stem cell therapies, and sustained-release devices.
Our report on the glaucoma pharmaceuticals market, now in its fifth edition, is a leading industry source for accurate and relevant information on all aspects of the glaucoma pharmaceuticals market. The glaucoma pharmaceuticals market is one of the largest and most complex market segments in ophthalmology with a variety of drug classes, as well as proprietary and generic versions of many drugs. Current ocular hypotensive medication classes used to treat glaucoma were developed 20 years ago or more, and generic versions of these medications are now in widespread use.
New and updated estimates of glaucoma populations around the world
Analysis of two new classes glaucoma therapeutics launched in the US in 2018: nitric oxide-donating compounds and rho kinase (ROCK) inhibitors
Expanded discussions of genetics, gene therapies, stem cell therapies, and sustained-release devices
2 licensing types are available for this report:
The price of the report is $6,800 for a single-user license.
The price of the enterprise license is $10,200 (includes supplemental Excel file with all the tables and figures in the report).
Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.
SINGLE USER LICENSE
The Single User License allows for the use of a report by a single user within one corporate location.
The report paper copy may not be reproduced (additional paper copies available for purchase).
Report PDF copy can not be copied (if purchased) and must remain on one computer (not a company server).
Only a single copy of the publication may be printed for internal use.
Users may include information in the report in presentations and internal reports by providing full copyright credit to Market Scope.
Users may not share the report (or any information contained therein) with any other person or persons outside the corporate location for which the report is purchased.
The Enterprise License allows for the use of a report by unlimited users within the purchasing organization.
Purchasing organization shall have the right to share the report with third parties. (investors, consultants, etc.) from time to time under the global license agreement, provided that such third parties have a confidentiality agreement with the purchasing organization and agree to be bound by the terms of the global license agreement.
Employees of the purchasing organization can include information given in the report in presentations and internal reports by providing full copyright credit to Market Scope.
Purchase price includes both a paper copy and printable PDF file of the report. (purchasing organization may print multiple copies for use within the organization)
Purchase price includes a supplemental Excel file containing all the tables and figures included in the purchased report.
Want to Purchase the Full Report?
Register A Corporate Account
A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.